Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05800132

Diagnostic Performance of Breast Cancer Screening Second Reading Process Assisted by AI

The goal of this clinical trial is to compare, for the second reading of screening mammograms, the standard of care with an AI assisted scenario.

The main questions it aims to answer are:

* will the experimental pathway be non-inferior to the standard pathway? * will the experimental pathway be economically superior to the standard pathway?

Participants will receive screening mammograms, as part of the breast cancer screening program. Researchers will compare the interpretation made by the second reader in the standard pathway with the AI assisted interpretation made by a different reader in the experimental pathway.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year–74 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Centre de radiologie Les Défensions, Aubagne, France

Loading trial locations.

About this study

All mammograms eligible for a second reading, and included in the study, go through 2 arms:

  • Conventional second reading by a radiologist accredited to do second reading in France (L2 control arm),
  • Second reading assisted by the AI (L2-AI experimental arm): mammograms will be read by the AI first and only if deemed suspicious, a radiologist accredited to do second reading in France will review them.

The most pejorative assessment among the two arms is used as the final decision: if both arms consider the mammogram as negative, the participant won't be recalled, if one arm consider the mammogram as positive, the participant will be called back for further examinations.

Clinical performances and economical impacts of both scenarii will be compared.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Affiliated to the French social security system
  • Whose mammograms meet the following characteristics: 4 (2 per breast, CC and MLO) meeting local regulatory standards and with correct DICOM metadata,
  • Whose mammograms have been determined to be normal or to have benign lesions by the radiologist who performed the first reading of the images (L1) in the framework of the organized breast cancer screening program
  • Having expressed her willingness to participate in the study, to undergo all the procedures and to make herself available for the expected duration of their participation,
  • Having completed and signed the informed consent form.

Exclusion criteria

  • Woman with breast implants,
  • With clinical symptoms of breast cancer,
  • With a history of breast surgery (breast reduction or surgery for benign lesion),
  • Pregnant or breastfeeding,
  • With medical conditions that may interfere with her ability to understand the requirements of the protocol or give informed consent,
  • Deprived of liberty by judicial or administrative order,
  • Participant whose mammogram images have at least one of the following defects: poor quality of the images, non-standard mammography (projection, magnification, compression), ML/LM/SIO/XCCL or XCCM view.

Treatment and study plan

MammoScreen

Device

Diagnostic reading aid for breast cancer screening

Primary outcomes

  1. Recall rate

    Time frame: End of the inclusion period 24 months

    Number of patients that are called back for further examinations divided by the total number of patient receiving a second reading.

Secondary outcomes

  1. Cancer detection rate

    Time frame: End of the inclusion period 24 months

    Number of biopsy proven cancers divided by the total number of patient receiving a second reading

  2. Sensitivity and Specificity

    Time frame: End of the follow_up period 48 months

    True and false-positive rate

  3. Economic impact

    Time frame: End of the follow_up period 48 months

    Difference in direct medical costs between the two arms Difference in annual budgetary impact on the French National Health Insurance between the two arms

  4. Time-to-results

    Time frame: End of the inclusion period 24 months

    Time period [in days] between the day of the screening and the access to results

  5. Reading time

    Time frame: End of the inclusion period 24 months

    Time needed [in seconds] to interpret a mammogram

Study contacts

Contact information is provided by the study sponsor or research team.

Brigitte Seradour

CONTACT

[email protected]

06 09 88 38 64

Patrice Heid

CONTACT

[email protected]

06 09 07 83 67

Sponsors and collaborators

Lead sponsor

Therapixel

Industry

Registry information

Official study title

Évaluation de la Performance Diagnostique du dépistage du Cancer du Sein, Pour Une Seconde Lecture Des clichés de Mammographie assistée du Dispositif médical à Base d'Intelligence Artificielle MammoScreen

Acronym: IMA-L2

Important dates

Study start
2023
Primary completion
2025
Study completion
2027
First posted
Apr 5, 2023
Registry last updated
Apr 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.